Association of early dapagliflozin initiation with subclinical changes in cardiac function during anticancer therapy

Clicks: 1
ID: 323369
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #158 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Subclinical cardiac dysfunction involving myocardial deformation, diastolic mechanics, left atrial (LA) remodeling may develop during cardiotoxic anticancer therapy, while the impact of early cardioprotective intervention in routine practice remains unclear. Aim To evaluate the association between early dapagliflozin initiation and 12-month subclinical changes in left ventricular (LV) mechanics and LA structure and function during anticancer therapy. Methods This multicenter retrospective study included 149 patients with HER2-positive breast cancer treated with anthracycline-based chemotherapy followed by trastuzumab across four centers. Dapagliflozin 10 mg once daily was prescribed at the treating physician’s discretion. Patients were classified as early dapagliflozin (≤3 months; n=67) versus no dapagliflozin use (n=82). Transthoracic echocardiography was performed at baseline, 6, 12 months. LV global longitudinal strain (GLS), tissue Doppler e′ velocities, average E/e′, LV ejection fraction (LVEF), indexed LA volumes (LAVmax, LAVmin) with total LA emptying function (LAEF) were assessed. Longitudinal changes were analyzed using linear mixed-effects models adjusted for baseline variables. Results Baseline clinical and echocardiographic characteristics were comparable between groups. Over 12 months, GLS deteriorated from −20.3 ± 1.9% to −17.9 ± 2.1% in the early dapagliflozin group, compared with −19.6 ± 2.1% to −15.8 ± 2.5% in patients without dapagliflozin (p<0.001). Average E/e′ increased from 9.8 ± 2.0 to 12.5 ± 2.4 versus 10.6 ± 2.3 to 15.3 ± 2.9, respectively (p<0.001). LAEF declined from 62.1 ± 7.8% to 56.2 ± 7.9% with early dapagliflozin and to 47.1 ± 9.8% without dapagliflozin (p<0.001). Indexed LAVmin increased from 9.5 ± 3.8 to 13.0 ± 4.5 ml/m² versus 10.8 ± 4.1 to 18.1 ± 5.8 ml/m², respectively (p<0.001). LVEF remained within the normal range in both groups throughout follow-up. Conclusion Early dapagliflozin initiation during anthracycline–trastuzumab therapy was associated with better preservation of LV mechanics and LA remodeling over 12 months.
Reference Key
openalex_W7172283450 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors L Hazarapetyan, H G Hayrapetyan, M A Chivchyan, P H Zelveian, S V Grigoryan
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.120
URL
https://doi.org/10.1093/eurheartjsupp/suag097.120
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.